Capecitabine Tablet, Film Coated
Product Images NDC 51407-640

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 51407-640). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-639-60ol.jpg (51407 639 60ol)

Label for Capecitabine 150 mg film-coated tablets, a cytotoxic agent, manufactured by Teva Czech Industries s.r.o. and marketed by GSMS, Incorporated. The label states it contains 60 tablets and includes storage instructions, usage cautions, and a barcode. It emphasizes prescription use (Rx Only).*

FDA Label Image

51407-640-12ol.jpg (51407 640 12ol)

Capecitabine 500 mg film-coated tablets label, USP, marketed by GSMS Incorporated with 120 tablets per container. It is identified as a cytotoxic agent and includes instructions for pharmacists to dispense patient information. The label also features storage conditions, warnings to keep tightly closed and out of reach of children, and manufacturing information by Teva Czech Industries s.r.o. The NDC number is 51407-640-12.*

FDA Label Image

Structural Formula (Image 1)

Chemical structure of Capecitabine, an oral film-coated tablet used as a prescription drug. The diagram depicts the molecular arrangement of atoms and bonds characteristic of Capecitabine's chemical composition.*

FDA Label Image

Metabolic Pathway (Image 2)

Chemical structure diagram illustrating the enzymatic conversion pathway of Capecitabine to its metabolites 5'-DFCR, 5'-DFUR, and 5-FU, showing structure changes catalyzed by Carboxylesterase, Cyd deaminase, and dThdPase enzymes.*

FDA Label Image

Figure 1 (Image 3)

A survival curve line graph comparing two treatment groups: Capecitabine (solid line) and 5-FU + Leucovorin (dashed line). The x-axis shows months since randomization from 0 to 96, and the y-axis represents survival probability from 0 to 1. The chart includes numbers at risk for each group at various time points below the x-axis.*

FDA Label Image

Figure 2 (Image 4)

A survival curve chart comparing two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line). The y-axis represents survival probability from 0.0 to 1.0, and the x-axis shows months since randomization from 0 to 96. Below the x-axis is a table showing the number of patients at risk over time for each treatment group.*

FDA Label Image

Figure 3 (Image 5)

A line graph comparing estimated probability over time (days) between two treatment groups: 5-FU plus Leucovorin (Mayo Regimen) with a dashed line and Capecitabine 1250 mg/sqm twice daily intermittent with a solid line. The x-axis shows time in days up to 1500, and the y-axis shows estimated probability from 0 to 1. An arrow marks approximately day 391-392 with a horizontal and vertical dashed line.*

FDA Label Image

Figure 4 (Image 6)

A line graph showing estimated probability on the Y-axis versus time in days on the X-axis, comparing two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily with intermittent Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph indicates survival probabilities over approximately 800 days, with marked points at days 128 and 186.*

FDA Label Image

Figure 5 (Image 7)

A survival curve chart depicting estimated probability over time (in days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph shows probability decreasing over approximately 800 days with marked points around 351.5 and 442.0 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.